Long-Term Survival after T-cell Lymphoblastic Lymphoma Treated with One Cycle of Hyper-CVAD Regimen.
- Author:
Il Hwan RYU
1
;
In Sung CHO
;
Ah Jeong RYU
;
Min Gyu KIM
;
Jae Woong JEON
;
Joo Seok KIM
;
Jae Joon LEE
;
Ji Wook CHOI
;
Dong Wook KANG
Author Information
- Publication Type:Case Report
- Keywords: Precursor T-cell lymphoblastic leukemia-lymphoma; Remission induction; CVAD protocol
- MeSH: Adult; Central Nervous System; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Therapy; Female; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma*; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; T-Lymphocytes*; Vincristine
- From:Cancer Research and Treatment 2015;47(1):115-119
- CountryRepublic of Korea
- Language:English
- Abstract: T-lymphoblastic lymphoma (T-LBL) is a rare form of aggressive non-Hodgkin's lymphoma. The standard approach for management of T-LBL involves intensive multiagent chemotherapy regimens for induction and consolidation phases with central nervous system prophylaxis and a maintenance phase lasting 12-18 months. We report on a case of long-term survival after one cycle of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) and high-dose methotrexate. A 30-year-old woman diagnosed with T-LBL with a large mediastinal mass underwent one cycle of hyper-CVAD. Four days after the start of treatment, the mediastinal mass was markedly reduced. Treatment continued with one cycle of consolidation chemotherapy, comprising high-dose methotrexate and high-dose cytarabine. The patient then refused all further chemotherapeutic treatment. Seven years have passed without relapse.
